Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(8):692–698. doi: 10.1111/j.1349-7006.2003.tb01504.x

DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma

Yoichi Hamai 1,2, Naohide Oue 1, Yoshitsugu Mitani 1, Hirofumi Nakayama 1, Reiko Ito 1, Keisuke Matsusaki 3, Kazuhiro Yoshida 2, Tetsuya Toge 2, Wataru Yasui 1,✉
PMCID: PMC11160177  PMID: 12901794

Abstract

The SWI/SNF proteins are ATP‐dependent chromatin remodeling enzymes that have been implicated in the regulation of gene expression. Recent studies have shown that members of the SWI/ SNF superfamily can function as tumor suppressor genes. DNA methylation and transcriptional inactivation of the HLTF gene, which is a homologue to the SWI/SNF genes, have been observed in colon cancer. In the present study, we studied the DNA methylation status of the HLTF gene by methylation‐specific PCR in 50 gastric carcinoma tissues, and seven gastric carcinoma cell lines and compared the methylation status with the levels of HLTF mRNA expression. DNA methylation of the HLTF gene was found in 25 (50%) of 50 gastric carcinomas, and levels of HLTF mRNA were associated with methylation status of HLTF (P=0.027; Mann‐Whitney U test). No correlations were found between HLTF mRNA levels and DNA methylation and T grade, N grade, tumor stage, or histological type. In corresponding non‐neoplastic mucosae, DNA methylation of the HLTF gene was found in 1 (7%) of 15 samples. The methylated allele was not detected in any of 10 normal gastric mucosae from 10 healthy volunteers. Among seven gastric carcinoma cell lines, the KATO‐III cell line showed loss of HLTF mRNA expression associated with DNA methylation. This loss was rectified by treatment with both Aza‐2′‐deoxycytidine, a demethylating agent, and trichostatin A, a histone deacetylase inhibitor. Chromatin immunoprecipitation assay revealed that the acetylation levels of histones H3 and H4 in the 5’CpG island of the HLTF gene were inversely associated with DNA methylation status. These results suggest that transcriptional inactivation of HLTF by aberrant DNA methylation and histone deacetylation may be involved in stomach carcinogenesis through down‐regulation of HLTF expression.

References

  • 1. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gas-troenterol 2000; 35: 111–5. [PubMed] [Google Scholar]
  • 2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–28. [DOI] [PubMed] [Google Scholar]
  • 3. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription Trends Genet 1997; 13: 444–9. [DOI] [PubMed] [Google Scholar]
  • 4. Razin A, Cedar H. DNA methylation and gene expression. Microbiol Rev 1991; 55: 451–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686–92. [DOI] [PubMed] [Google Scholar]
  • 6. Kikuchi T, Itoh F, Toyota M, Suzuki H, Yamamoto H, Fujita M, Hosokawa M, Imai K. Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. Int J Cancer 2002; 97: 272–7. [DOI] [PubMed] [Google Scholar]
  • 7. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285–91. [DOI] [PubMed] [Google Scholar]
  • 8. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inacti‐vation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001; 61: 7034–8. [PubMed] [Google Scholar]
  • 9. Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ. Transcriptional silencing of cyclooxygenase‐2 by hyper‐methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res 2001; 61: 4628–35. [PubMed] [Google Scholar]
  • 10. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y, Imai K. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer 1999; 83: 309–13. [DOI] [PubMed] [Google Scholar]
  • 11. Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000; 80: 689–95. [DOI] [PubMed] [Google Scholar]
  • 12. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090–5. [PubMed] [Google Scholar]
  • 13. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high‐frequency microsatellite instability. Cancer Res 1999; 59: 159–4. [PubMed] [Google Scholar]
  • 14. Sato K, Tamura G, Tsuchiya T, Endoh Y, Usuba O, Kimura W, Motoyama T. Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer. Br J Cancer 2001; 85: 199–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 2000; 19: 3642–6. [DOI] [PubMed] [Google Scholar]
  • 16. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ. E‐Cadherin gene promoter hyper‐methylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569–73. [DOI] [PubMed] [Google Scholar]
  • 17. Kaneda A, Kaminishi M, Nakanishi Y, Sugimura T, Ushijima T. Reduced expression of the insulin‐induced protein 1 and p41 Arp2/3 complex genes in human gastric cancers. Int J Cancer 2002; 100: 57–62. [DOI] [PubMed] [Google Scholar]
  • 18. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62: 6645–50. [PubMed] [Google Scholar]
  • 19. Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, Yasui W. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 2001; 93: 805–9. [DOI] [PubMed] [Google Scholar]
  • 20. Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K, Yasui W. Distinct promoter hypermethylation of p16INK4a CDH1 and RAR‐beta in intestinal diffuse‐adherent and diffuse‐scattered type gastric carcinomas. J Pathol 2002; 198: 55–9. [DOI] [PubMed] [Google Scholar]
  • 21. Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K, Yasui W. Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 2003; 64: 423–9. [DOI] [PubMed] [Google Scholar]
  • 22. Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz SD. HLTF gene silencing in human colon cancer. Proc Natl Acad Sci USA 2002; 99: 4562–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Muchardt C, Yaniv M. ATP‐dependent chromatin remodelling: SWI/SNF and Co. are on the job. J Mol Biol 1999; 293: 187–98. [DOI] [PubMed] [Google Scholar]
  • 24. Sudarsanam P, Winston F. The Swi/Snf family nucleosome‐remodeling complexes and transcriptional control. Trends Genet 2000; 16: 345–51. [DOI] [PubMed] [Google Scholar]
  • 25. Versteege I, Sevenet N, Lange J, Rousseau‐Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O. Truncating mutations of hSNF5/ INI1 in aggressive paediatric cancer. Nature 1998; 394: 203–6. [DOI] [PubMed] [Google Scholar]
  • 26. Schmitz U, Mueller W, Weber M, Sevenet N, Delattre O, von Deimling A. INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 2001; 84: 199–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Yuge M, Nagai H, Uchida T, Murate T, Hayashi Y, Hotta T, Saito H, Kinoshita T. HSNF5/INI1 gene mutations in lymphoid malignancy. Cancer Genet Cytogenet 2000; 122: 37–42. [DOI] [PubMed] [Google Scholar]
  • 28. Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, Ghaffari S, Iliev D, Penn B, Woodland AM, Smith R, Salada G, Carillo A, Laity K, Gupte J, Swedlund B, Tavtigian SV, Teng DH, Lees E. BRG1 a component of the SWI‐SNF complex is mutated in multiple human tumor cell lines. Cancer Res 2000; 60: 6171–7. [PubMed] [Google Scholar]
  • 29. Hibi K, Nakayama H, Kanyama Y, Kodera Y, Ito K, Akiyama S, Nakao A. Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer 2003; 104: 433–6. [DOI] [PubMed] [Google Scholar]
  • 30. Bird AP, Wolffe AP. Methylation‐induced repression‐belts braces and chromatin. Cell 1999; 99: 451–4. [DOI] [PubMed] [Google Scholar]
  • 31. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation‐induced gene silencing in cancer cells: correlation of accessibility methylation MeCP2 binding and acetylation. Nucleic Acids Res 2001; 29: 4598–606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Lauren P. The two histological main types of gastric carcinoma. Diffuse and so‐called intestinal type carcinoma: an attempt at histological classification. Acta Pathol Microbiol Scand 1965; 64: 31–49. [DOI] [PubMed] [Google Scholar]
  • 33. Sobin LH, Wittekind C, editors. TNM classification of malignant tumors. 5th ed. New York : Wiley‐Liss; 1997. p. 59–62. [Google Scholar]
  • 34. Ochiai A, Yasui W, Tahara E. Growth‐promoting effect of gastrin on human gastric carcinoma cell line TMK‐1. Jpn J Cancer Res 1985; 76: 1064–71. [PubMed] [Google Scholar]
  • 35. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c‐myc oncogene. Cancer Res 1991; 51: 381–6. [PubMed] [Google Scholar]
  • 36. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation‐specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Ferreira R, Naguibneva I, Mathieu M, Ait‐Si‐Ali S, Robin P, Pritchard LL, Harel‐Bellan A. Cell cycle‐dependent recruitment of HDAC‐1 correlates with deacetylation of histone H4 on an Rb‐E2F target promoter. EMBO Rep 2001; 2: 794–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Sentani K, Oue N, Kondo H, Kuraoka K, Motoshita J, Ito R, Yokozaki H, Yasui W. Increased expression but not genetic alteration of BRG1 a component of the SWI/SNF complex is associated with the advanced stage of human gastric carcinomas. Pathobiology 2001; 69: 315–20. [DOI] [PubMed] [Google Scholar]
  • 39. Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002; 21: 2741–9. [DOI] [PubMed] [Google Scholar]
  • 40. Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T, Imai K. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 2002; 86: 1817–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Walia H, Chen HY, Sun JM, Holth LT, Davie JR. Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA. J Biol Chem 1998; 273: 14516–22. [DOI] [PubMed] [Google Scholar]
  • 42. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re‐expression of genes silenced in cancer. Nat Genet 1999; 21: 103–7. [DOI] [PubMed] [Google Scholar]
  • 43. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000; 19: 1556–63. [DOI] [PubMed] [Google Scholar]
  • 44. Bovenzi V, Momparler RL. Antineoplastic action of 5‐aza‐2′‐deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001; 48: 71–6. [DOI] [PubMed] [Google Scholar]
  • 45. Ding H, Descheemaeker K, Marynen P, Nelles L, Carvalho T, Carmo‐Fonseca M, Collen D, Belayew A. Characterization of a helicase‐like transcription factor involved in the expression of the human plasminogen activator inhibitor‐1 gene. DNA Cell Biol 1996; 15: 429–42. [DOI] [PubMed] [Google Scholar]
  • 46. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611–9. [DOI] [PubMed] [Google Scholar]
  • 47. Ossowski L, Russo‐Payne H, Wilson EL. Inhibition of urokinase‐type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274–81. [PubMed] [Google Scholar]
  • 48. Grondahl‐Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert‐Toft M. High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513–21. [PubMed] [Google Scholar]
  • 49. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type‐1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992; 50: 208–14. [DOI] [PubMed] [Google Scholar]
  • 50. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase‐type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 1997; 79: 878–83. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES